# HMI-115

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/hmi-115
Canonical HTML page: https://getbiobrief.com/entity/hmi-115

## Timeline

- **2026-03-25**: Phase III Initiation — First patient dosed in the pivotal Phase III clinical trial for endometriosis.
- **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China.
- **2026-01**: Regulatory Designations — HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
- **2026**: Trial Expansion — Continued enrollment across global multicenter sites for the 24-week study.
- **2025-Q4**: Phase II Completion — Global multicenter Phase II trial results published in The Lancet showing efficacy and safety.
- **2023-06-15**: Phase II Completion — Positive results from Phase II studies demonstrate pain reduction and safety.
- **2019-04-01**: Licensing Agreement — Hope Medicine acquires global rights for HMI-115 from Bayer.

## Recent coverage (2 stories)

### Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy
2026-03-25 12:13:15 · Sentiment: Positive · Impact: 7/10 · Sources: 10

Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Full story: https://getbiobrief.com/story/hope-medicine-hmi-115-phase-iii-endometriosis

### Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115
2026-03-25 02:01:10 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Full story: https://getbiobrief.com/story/hope-medicine-phase-3-endometriosis-trial-hmi-115

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.